Glycaemic control improves perfusion recovery and VEGFR2 protein expression in diabetic mice following experimental PAD

Cardiovascular Research

Volumn 101, Issue 3, 2014, Pages 364-372

  Dokun, Ayotunde O ^a   Chen, Lingdan ^a   Lanjewar, Swapnil S ^a   Lye, Robert John ^a   Annex, Brian H ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Diabetes; Glycaemic control; Hyperglycaemia; Peripheral arterial disease; Proteasome; VEGF receptor

Indexed keywords

DIABETES; GLYCAEMIC CONTROL; HYPERGLYCAEMIA; PERIPHERAL ARTERIAL DISEASE; PROTEASOME; VEGF RECEPTOR;

ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; DISEASE MODELS, ANIMAL; ENDOTHELIAL CELLS; HINDLIMB; HUMANS; HYPERGLYCEMIA; ISCHEMIA; MICE; PERFUSION; PERIPHERAL ARTERIAL DISEASE; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84894519880     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvt342     Document Type: Article

References (26)

1. Melton LJ, Macken KM, Palumbo PJ, Elveback LR. Incidence and prevalence of clinical peripheral vascular disease in a population-based cohort of diabetic patients. Diabetes Care 1980;3:650-654.
2. Welborn TA, Knuiman M, McCann V, Stanton K, Constable IJ. Clinical macrovascular disease in Caucasoid diabetic subjects: logistic regression analysis of risk variables. Diabetologia 1984;27:568-573.
3. Selvin E, Wattanakit K, SteffesMW, Coresh J, Sharrett AR. HbA1c and peripheral arterial disease in diabetes. Diabetes Care 2006;29:877-882.
4. Jude EB, Eleftheriadou I, Tentolouris N. Peripheral arterial disease in diabetes-a review. Diabetic Med 2010;27:4-14.
5. UKPDS Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). The Lancet 1998;352:837-853.
6. Couffinhal T, Silver M, Zheng L, Kearney M, Witzenbichler B, Isner J. Mouse model of angiogenesis. Am J Pathol 1998;152:1667-1679.
7. Hazarika S, Dokun AO, Li Y, Popel AS, Kontos CD, Annex BH. Impaired angiogenesis after hindlimb ischemia in type 2 diabetes mellitus: differential regulation of vascular endothelial growth factor receptor 1 and soluble vascular endothelial growth factor receptor 1. Circ Res 2007;101:948-956.
8. Rivard A, Silver M, Chen D, Kearney M, Magner M, Annex B et al. Rescue of diabetesrelated impairment of angiogenesis by intramuscular gene therapy with adeno-VEGF. Am J Pathol 1999;154:355-363.
9. Tamarat R, Silvestre J-Sb, Huijberts M, Benessiano J, Ebrahimian TG, Duriez M et al. Blockade of advanced glycation end-product formation restores ischemia-induced angiogenesis in diabetic mice. Proc Natl Acad Sci 2003;100:8555-8560.
10. Ebrahimian TG, Heymes C, You D, Blanc-Brude O, Mees B, Waeckel L et al. NADPH oxidase-derived overproduction of reactive oxygen species impairs postischemic neovascularization in mice with type 1 diabetes. Am J Pathol 2006;169:719-728.
11. Li Y, Hazarika S, Xie D, PippenAM, Kontos CD, Annex BH. In mice with type 2 diabetes, a vascular endothelial growth factor (VEGF)-activating transcription factor modulates VEGF signaling and induces therapeutic angiogenesis after hindlimb ischemia. Diabetes 2007;56:656-665.
12. Thangarajah H, Yao D, Chang EI, Shi Y, Jazayeri L, Vial IN et al. The molecular basis for impaired hypoxia-induced VEGF expression in diabetic tissues. Proc Natl Acad Sci 2009;106:13505-13510.
13. Moriya J, WuX, Zavala-Solorio J, Ross J, Liang XH, Ferrara N. PDGF-C promotes revascularization in ischemic limbs of diabetic mice. J Vasc Surg 2013. http://dx.doi.org/10. 1016/j.jvs.2013.04.053.
14. Olsson A-K, Dimberg A, Kreuger J, Claesson-Welsh L. VEGF receptor signalling-in control of vascular function. Nat Rev Mol Cell Biol 2006;7:359-371.
15. Cébe-Suarez S, Zehnder-Fjällman A, Ballmer-Hofer K. The role of VEGF receptors in angiogenesis; complex partnerships. Cell Mol Life Sci 2006;63:601-615.
16. Hoeben A, Landuyt B, Highley MS, Wildiers H, Van OosteromAT, De Bruijn EA. Vascular endothelial growth factor and angiogenesis. Pharmacol Rev 2004;56:549-580.
17. Wang J, TakeuchiT, Tanaka S, Kubo SK, KayoT, LuDet al.Amutation in the insulin 2 gene induces diabetes with severe pancreatic beta-cell dysfunction in the Mody mouse. J Clin Invest 1999;103:27-37.
18. Dai Q, Huang J, Klitzman B, Dong C, Goldschmidt-Clermont PJ, March KL et al. Engineered zinc finger-activating vascular endothelial growth factor transcription factor plasmid DNA induces therapeutic angiogenesis in rabbits with hindlimb ischemia. Circulation 2004;110:2467-2475.
19. McClung JM, McCord TJ, Keum S, Johnson S, Annex BH, Marchuk DA et al. Skeletal muscle specific genetic determinants contribute to the differential strain-dependent effects of hindlimb ischemia in mice. Am J Pathol 2012;180:2156-2169.
20. Xie D, Li Y, Reed EA, Odronic SI, Kontos CD, Annex BH. An engineered vascular endothelial growth factor-activating transcription factor induces therapeutic angiogenesis in ApoE knockout mice with hindlimb ischemia. J Vasc Surg 2006;44:166-175.
21. Handelsman Y, Mechanick J, Blonde L, Grunberger G, Bloomgarden Z, Bray G et al. American Association of Clinical Endocrinologists Medical Guidelines for clinical practice for developing a diabetes mellitus comprehensive care plan. Endocrine Pract 2011; 17:1-53.
22. Zimmermann RC, Hartman T, Bohlen P, Sauer MV, Kitajewski J. Preovulatory treatment of mice with anti-VEGF receptor 2 antibody inhibits angiogenesis in corpora lutea. Microvasc Res 2001;62:15-25.
23. MeyerRD, Srinivasan S, Singh AJ, Mahoney JE, Gharahassanlou KR, Rahimi N. PEST motif serine and tyrosine phosphorylation controls vascular endothelial growth factor receptor 2 stability and downregulation. Mol Cell Biol 2011;31:2010-2025.
24. Balasubramanyam M, Sampathkumar R, Mohan V. Is insulin signaling molecules misguided in diabetes for ubiquitin-proteasome mediated degradation? Mol Cell Biochem 2005;275:117-125.
25. Villalta SA, Lang J, Kubeck S, Kabre B, Szot GL, Calderon B et al. Inhibition of VEGFR-2 reverses type 1 diabetes inNODmice by abrogating insulitis and restoring islet function. Diabetes 2013;62:2870-2878.
26. Izumi T, Yokota-Hashimoto H, Zhao S, Wang J, Halban PA, Takeuchi T. Dominant negative pathogenesis by mutant proinsulin in the Akita diabetic mouse. Diabetes 2003;52: 409-416.